Celastrol enhances bone wound healing in rats

Celastrol and wound healing

Abstract

Bone fracture is one of the most common injuries in the human musculoskeletal system. This study was performed to investigate the effects of celastrol on bone wound healing in rats. Bone wound models of Sprague-Dawley rats were treated with low (10 μg/kg) and high (100 μg/kg) celastrol for 14 days. Serum calcium (Ca), phosphorus (P), and alkaline phosphatase (ALP) contents, bone mechanical properties, bone mineral density (BMD), and the levels of osteogenesis-related and inflammation-related proteins were assessed at the end of the experiments. Rats feeding with celastrol grew normally as control. Compared with model, celastrol administration significantly increased fracture strength, elastic load (0.12 vs 0.16 kg/m), bending energy (11.23 vs 14.23 n x mm), and BMD (0.49 vs 0.54 g/cm3), particularly at a high dose. Serum Ca (2.2 vs 2.7 mmol/L) and ALP (217.3 vs 245.8 IU/L) contents were significantly increased after a high dose celastrol administration, although P content did not change. Western blot analyses showed that OPG (0.72 vs 1.15) and COL-1 (0.20 vs 0.42) but not RUNX2 were upregulated significantly after celastrol administration, and IL-1α (0.82 vs 0.37), IL-6 (0.62 vs 0.28), MCP-1(0.68 vs 0.18), and VEGF (0.62 vs 0.42) were significantly downregulated, while IFN-γ was upregulated (0.29 vs 0.46). Our data demonstrate that celastrol effectively promotes the healing of bone wound in rats and may be further explored as a therapeutic agent to treat bone fracture.